Welcome to our dedicated page for NUGEN MEDICAL DEVICES news (Ticker: NGMDF), a resource for investors and traders seeking the latest updates and insights on NUGEN MEDICAL DEVICES stock.
NuGen Medical Devices Inc. develops needle-free devices for subcutaneous drug delivery, centered on the InsuJet™ system for insulin administration and related consumables. Company news commonly covers commercialization of InsuJet and EziAutoJector® through distributors and pharmacy channels, product availability in markets such as France and the United Kingdom, and medical-device regulatory updates tied to national approvals and licensing.
NuGen updates also include research and development for prefilled and cartridge-based needle-free injection formats, patent activity for Ready-to-Fill COP/COC nozzles and the Prefilled Nozzle platform, annual financial results, and governance changes involving financial reporting functions.
NuGen Medical Devices Inc. has commenced trading on the OTCQB under the symbol NGMDF, effective July 27, 2022. This marks a significant milestone, enhancing the accessibility for American investors. The company continues to trade on the TSX Venture Exchange under the symbol NGMD. NuGen is also awaiting approval for DTC eligibility, facilitating electronic settlement and transfer of shares in the U.S. The company specializes in needle-free medical devices, including the InsuJet™ and PetJet™, targeting diabetes, veterinary medicine, and vaccines.